Progressing development of therapies for retinal vascular disorders and diabetic eye disease
Patrik De Haes, M.D., CEO of Oxurion, and Thomas Clay, Chairman of the Board, review the year 2019.
Pravin Dugel, M.D.: “Biological signal for efficacy of THR-149”
“As an investigator of THR-149, I was encouraged to see the results from its clinical phase 1 trial", Pravin Dugel, M.D., says.
Phase 1 trial showed THR-149 is a highly potent plasma kallikrein inhibitor to treat DME
In 2019, Oxurion announced positive topline data for the compound THR-149, a highly potent plasma kallikrein inhibitor to treat diabetic macular edema (DME).
Arshad Khanani: “Initial data of phase 1 trial of THR-687 point to clinical efficacy”
Arshad Khanani, M.D., M.A. about the clinical phase 1 data of THR-687.
Positive phase 1 data indicate THR-687 could be an effective therapy for patients with DME
Oxurion kick-started 2020 with positive topline data from phase 1 clinical trial evaluating THR-687 for treatment of DME.
Professor Alan Stitt: Researching the AMD pathway
An interview with Alan Stitt about research in the AMD field.
Oxurion NV Partners with Prevent Blindness to Educate Public on Diabetes-related Eye Disease
Both Oxurion and Prevent Blindness join forces during November to educate the public on risk factors, symptoms, treatment options, and financial assistance resources.
Research opportunities for treating age-related macular degeneration
Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.
3 reasons why we need to raise diabetic eye disease awareness
Diabetic eye diseases affect millions of people globally, and still there's a high unmet need in diagnosis and treatment. It's high time to get the message across to risk groups.
9 striking facts about diabetic eye disease
In this post, we’ll share some striking facts and numbers about diabetes and diabetic eye disease.
Sehnaz Karadeniz on tackling diabetes and related vision problems
Diabetic eye disease is currently one of the leading causes of preventable blindness in the working population worldwide. Early treatment and diagnosis is crucial for prevention.
Creating Diabetic Eye Disease Awareness with Prevent Blindness
This November, in support of Diabetic Eye Disease Awareness Month, Oxurion is partnering with Prevent Blindness and its sight saving efforts.
Alan Stitt: “We need therapies fighting different hallmarks simultaneously”
PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains professor Alan Stitt.
“JETREA has a group of very loyal users worldwide”
Vinciane Vangeersdaele joined the Oxurion leadership team this past year. With extensive experience in commercializing pharmaceutical portfolios worldwide, including in ...